普吉岛当日送达

购物车

您的购物车为空

开始浏览

订单满 €500 免运费。

小计€0
前往结账
研究领域

运动表现研究

细胞能量、耐力和运动模拟剂。 以下是该领域每种化合物的已发表文献 — 共89项研究,其中67项发表于2023年后,每项均链接至来源记录。

最新

最新发表的研究

  • MOTS-C人体临床2026

    Circulating mitochondrial-derived microproteins at rest and in response to an acute bout of endurance exercise in individuals with cerebral palsy

    Experimental Physiology · 典型发育成人、典型发育青少年和脑瘫成人(GMFCS II-IV);急性耐力运动

    PubMed · 42349896
  • MOTS-C动物体内2026

    MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner

    Free Radical Biology and Medicine · 两个转基因小鼠品系(PGC-1alpha 和 AMPK 模型)给予 MOTS-c;骨骼肌线粒体生物能学

    PubMed · 41520850
  • MOTS-C人体临床2026

    Reduced serum and skeletal muscle MOTS c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction

    Scientific Reports · 40 名多囊卵巢综合征女性与 40 名年龄和 BMI 匹配的对照;血清和骨骼肌采样

    PubMed · 41680431
  • MOTS-C综述2026

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

    Sports Medicine · 体育医学中使用的获批和未获批肽的叙述性综述,包括线粒体来源肽

    PubMed · 41966639
  • MOTS-C人体临床2026

    Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss

    Journal of Clinical & Translational Endocrinology · 22 名瘦型和 32 名肥胖成人的横断面比较,其中 10 名在减肥手术后随访

    PubMed · 41551324
  • NAD+人体临床2026

    A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment

    Alzheimer's & Dementia · 12周 II 期双盲随机安慰剂对照先导试验,42名患有遗忘型轻度认知障碍的老年人(NR 组 n = 22,安慰剂组 n = 20)

    PubMed · 42478598
  • NAD+人体临床2026

    Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial

    Nature Medicine · 单臂开放标签 1/2 期试验,25名激素难治性或激素依赖性免疫性血小板减少症成人患者,NMN 450 mg 每日两次,持续2周,并有小鼠巨噬细胞支持性实验

    PubMed · 42056497
  • NAD+人体临床2026

    Safety and efficacy of individualised exercise and NAD+ precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial

    The Lancet Neurology · 2期单中心2×2析因随机对照试验,66名年龄10-40岁的Friedreich共济失调患者,12周基于体重的烟酰胺核糖苷(300-900 mg)和/或个性化家庭运动

    PubMed · 42009009

仅供研究使用。不得用于人体消费、诊断、治疗或预防任何疾病。本页面内容不构成医疗建议。